Inhaled Fluorinated Polymer Triggers Pyroptosis for Lung Cancer Immunotherapy
Advanced Healthcare Materials · 2026-11 · 15 (41)
DOI: 10.1002/adhm.71814 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 07.10.2026. Verfasst von Biyu Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Functional Polymer Materials Ministry of Education, College of Chemistry, Nanka…. Hauptthemen laut MEDLINE: Lung Neoplasms, Pyroptosis, Polymers, Immunotherapy. Die Arbeit nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Tianjin Science Foundation for Distinguished Young Scholars, Key Projects of Tianjin Science and Technology.
Abstract (Originalsprache)
Lung cancer imposes the highest cancer‐related mortality burden worldwide, while its responsiveness to immunotherapy is often constrained by the immunosuppressive pulmonary tumor microenvironment (TME) and tumor adaptations that buffer oxidative stress. Pyroptosis, a highly immunogenic form of programmed cell death that can be activated through mechanisms not strictly dependent on exogenous reactive oxygen species (ROS), offers a promising alternative for immune activation but remains challenging to induce effectively in vivo. Here, we report an inhalable fluorinated polymer nanoplatform (PFAP) that triggers mitochondrial dysfunction to initiate pyroptosis and thereby elicits potent antitumor immunity in the lung. PFAP integrates perfluoroalkyl segments with cationic domains to enhance interactions with mitochondrial membranes, while a detachable polyethylene glycol shell preserves nanoparticle stability during aerosolization and facilitates penetration of pulmonary barriers. Upon exposure to the acidic TME, PFAP restores membrane‐disruptive activity, leading to mitochondrial depolarization, Cyto C release, caspase‐3 activation, GSDME cleavage, and pyroptosis induction. In orthotopic and metastatic lung cancer models, inhaled PFAP achieves efficient lung delivery, elicits robust antitumor immunity, and suppresses tumor progression without detectable systemic toxicity. This work provides a nanomaterial‐based approach for inducing pyroptosis in lung cancer and highlights the potential of inhalable polymer systems for localized cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Functional Polymer Materials Ministry of Education, College of Chemistry, Nankai University, Tianjin, China.
- Frontiers Science Center For New Organic Matter, Nankai University, Tianjin, China.
- Academy For Advanced Interdisciplinary Studies, Nankai University, Tianjin, China.
Förderung
- National Natural Science Foundation of China
- Tianjin Science Foundation for Distinguished Young Scholars
- Key Projects of Tianjin Science and Technology
- Academy for Advanced Interdisciplinary Studies, Nankai University
- Frontiers Science Center for New Organic Matter, Nankai University
Zitieren
APA
Zhou, B., Feng, N., Xiao, J., Huang, Q., Li, Q., Bai, Y., & Liu, Y. (2026). Inhaled Fluorinated Polymer Triggers Pyroptosis for Lung Cancer Immunotherapy. Advanced Healthcare Materials, 15(41). https://doi.org/10.1002/adhm.71814
Vancouver
Zhou B, Feng N, Xiao J, Huang Q, Li Q, Bai Y, et al. Inhaled Fluorinated Polymer Triggers Pyroptosis for Lung Cancer Immunotherapy. Advanced Healthcare Materials. 2026;15(41). doi:10.1002/adhm.71814
BibTeX
@article{Zhou2026,
author = {Zhou, Biyu and Feng, Nana and Xiao, Jian and Huang, Qingqing and Li, Qiushi and Bai, Yating and Liu, Yang},
title = {Inhaled Fluorinated Polymer Triggers Pyroptosis for Lung Cancer Immunotherapy},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {41},
doi = {10.1002/adhm.71814}
}
EUVIMED